Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy
| Autor: | Jake R Thompson, Julia Lai-Kwon, Rachael L Morton, Alexander D Guminski, Maria Gonzalez, Victoria Atkinson, Shahneen Sandhu, Michael P Brown, Alexander M Menzies, Grant A McArthur, Serigne N Lo, Georgina V Long, Iris Bartula |
|---|---|
| Přispěvatelé: | Thompson, Jake R, Lai-Kwon, Julia, Morton, Rachael L, Guminski, Alexander D, Gonzalez, Maria, Atkinson, Victoria, Sandhu, Shahneen, Brown, Michael P, Menzies, Alexander M, McArthur, Grant A, Lo, Serigne N, Long, Georgina, V, Bartula, Iris |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Immunotherapy. 15:593-610 |
| ISSN: | 1750-7448 1750-743X 0237-4242 |
| DOI: | 10.2217/imt-2022-0262 |
| Popis: | Aims: To describe the health-related quality of life (HRQoL) of melanoma brain metastasis (MBM) patients throughout the first 18 weeks of ipilimumab–nivolumab or nivolumab treatment. Materials & methods: HRQoL data (European Organisation for Research and Treatment of Cancer's Core Quality of Life Questionnaire, additional Brain Neoplasm Module, and EuroQol 5-Dimension 5-Level Questionnaire) were collected as a secondary outcome of the Anti-PD1 Brain Collaboration phase II trial. Mixed linear modeling assessed changes over time, whereas the Kaplan–Meier method was used to determine median time to first deterioration. Results: Asymptomatic MBM patients treated with ipilimumab–nivolumab (n = 33) or nivolumab (n = 24) maintained baseline HRQoL. MBM patients with symptoms or leptomeningeal/progressive disease treated with nivolumab (n = 14) reported a statistically significant trend toward improvement. Conclusion: MBM patients treated with either ipilimumab–nivolumab or nivolumab did not report a significant deterioration in HRQoL within 18 weeks of treatment initiation. Clinical trial registration: NCT02374242 ( ClinicalTrials.gov ) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|